IPP Bureau
VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
By IPP Bureau - September 12, 2025
CRISPR-based detection enables highly specific molecular recognition
Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing
By IPP Bureau - September 12, 2025
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
iRegene Therapeutics secures series B+ financing
By IPP Bureau - September 12, 2025
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
A.forall expands US generics portfolio
By IPP Bureau - September 12, 2025
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
LGC opens CAD $100 million organic chemistry Center of Excellence in Canada
By IPP Bureau - September 12, 2025
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Lonza appoints Jason Berndt as Head of Group Operations
By IPP Bureau - September 12, 2025
Maria Soler Nunez appointed as Chief Quality Officer
Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries
By IPP Bureau - September 12, 2025
Hemant Surgical Industries receives order
Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
By IPP Bureau - September 11, 2025
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
By IPP Bureau - September 11, 2025
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Novo Nordisk to cut 9,000 jobs globally
By IPP Bureau - September 11, 2025
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093
By IPP Bureau - September 10, 2025
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Sirio secures TGA GMP certification to support strategic growth in Australia
By IPP Bureau - September 10, 2025
The Ma’anshan site approval covers pastilles, oral liquids, and powders
FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US
By IPP Bureau - September 10, 2025
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Cupid to acquire strategic stake in Mansam fragrance brand, Saudi Arabia
By IPP Bureau - September 10, 2025
Mansam, founded in 2022, is positioned as the first Arabian luxury fragrance brand with a vision for global expansion
